<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216099</url>
  </required_header>
  <id_info>
    <org_study_id>HOG GU03-67</org_study_id>
    <nct_id>NCT00216099</nct_id>
  </id_info>
  <brief_title>Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer</brief_title>
  <official_title>A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christopher Sweeney, MBBS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docetaxel-based therapy has been shown to prolong survival as first-line therapy for patients
      with hormone refractory prostate cancer (HRPC), and has become the standard of care. The
      beneficial effects of any therapy in HRPC may be diverse and include reduction in tumor bulk
      (when measurable), reduction in prostate-specific antigen PSA, reduction in symptoms
      (particularly pain), or stabilization of disease. Clear reductions in tumor bulk or PSA may
      provide objective evidence of a treatment effect, and stabilization of disease may be just as
      clinically meaningful in patients who are actively progressing prior to starting therapy.
      Pemetrexed has shown a broad array of activity in many diseases that until now were thought
      to be non-responsive to chemotherapy in the second-line setting.

      This trial is designed to further assess the efficacy, safety, tolerability, and
      pharmacogenetics of pemetrexed as a single agent in subjects with HRPC whose disease has
      progressed following one prior taxane-based chemotherapy regimen for HRPC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.

        -  Pemetrexed 500mg/m2 will be administered intravenously over approximately 10-minutes on
           Day 1 of a 21-day cycle.

        -  Folic Acid (350-1000 mcg. PO daily) will be taken by patients to reduce toxicity. At
           least 5 daily doses of folic acid must be taken during the 7-day period preceding the
           first dose of pemetrexed, and dosing should continue during the full course of therapy
           and for 21 days after the last dose of pemetrexed.

        -  Vitamin B12 (1000 Âµg) will be administered as an intramuscular injection during the week
           preceding the first dose of pemetrexed and every 3 cycles thereafter. Subsequent vitamin
           B12 injections may be given the same day as pemetrexed.

      Performance Status: Karnofsky Performance Status 70-100

      Life expectancy &gt; 12 weeks

      Hematopoietic:

        -  Absolute Neutrophil Count (ANC) &gt; 1500/mm3

        -  Platelet count &gt; 100,000/mm3

        -  Hemoglobin &gt; 9 g/dL

      Hepatic:

        -  Bilirubin &lt; 1.5 X upper limit of normal (unless due to Gilbert's disease)

        -  Alkaline phosphatase and Alanine Transanimase (ALT) (SGPT) &lt; 3 X upper limit of normal
           (ULN); may be &lt; 5 X ULN for patients with liver metastases. Alkaline phosphatase may be
           any value for patients with bone metastases.

      Renal:

        -  Calculated creatinine clearance &gt;45 mL/min based on the standard Cockroft and Gault
           formula

      Cardiovascular:

        -  No congestive heart failure requiring therapy or New York Heart Association (NYHA) class
           II or greater or active angina or known myocardial infarction within 12 months prior to
           study

        -  No unstable angina, uncontrolled congestive heart failure, or unstable symptomatic
           arrhythmia requiring medication within 6 months prior to being registered for protocol
           therapy

        -  Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation, paroxysmal
           supraventricular tachycardia, or controlled hypertension are eligible

      Pulmonary:

        -  Not specified
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall PSA Response</measure>
    <time_frame>Start of treatment until disease progression/recurrence (for life)</time_frame>
    <description>Best overall Prostate-Specific Antigen (PSA) response
PSA response is defined by a greater than or equal to 50% decline in PSA confirmed by a second PSA value at least 4 weeks after the first PSA response timepoint PSA Stable Disease is defined as less than a 50% decline in PSA and less than a 50% increase in PSA from baseline PSA progression is defined as greater than or equal to a 50% increase in PSA compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From study enrollment until death (for life)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OBJECTIVE Overall Response Rate</measure>
    <time_frame>Start of treatment until disease progression/recurrence (for life)</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST). Objective overall response rate is defined as Complete Response (CR) + Partial Response (PR)
Per RECIST:
CR= Disappearance of all target and non-target lesions and normalization of tumor marker level PR= Disappearance of all target lesions and persistence of non-target lesion(s) or maintenance of tumor marker level above normal limits OR at least a 30% decrease in the sum of the longest diameter, taking as reference the baseline sum longest diameter and disappearance of all non-target lesions or persistence of non-target lesion(s) or maintenance of tumor marker level above normal limits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Clinical Benefit</measure>
    <time_frame>Any time among evaluable subjects (for life)</time_frame>
    <description>A clinical benefit is defined as an improvement for at least 3 consecutive weeks in at least one of the following parameters without any sustained worsening in any other:
&gt; 50% reduction in analgesic consumption or &gt; 50% reduction in pain intensity or &gt; 20 point gain in performance status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>18 months</time_frame>
    <description>Safety and Tolerability was evaluated by reporting the percentage of patient who experienced grade 3 or 4 toxicities using Common Terminology Criteria for Adverse Events CTCAE v3.0 criteria. CTCAE grades the severity of an adverse event from 1-5 where 1=least severe and 5=death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFC1 G80A Genotype</measure>
    <time_frame>Screening</time_frame>
    <description>Samples for RFC1 G80A pharmacogenetic analysis were collected at screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Study enrollment until progression per RECIST or PSA (for life)</time_frame>
    <description>Progression per Response Evaluation Criteria in Solid Tumors (RECIST) or Prostate-Specific Antigen (PSA) Progression RECIST PD=at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions PSA progression=increase in PSA to &gt;50% above lowest level recorded on study. Two consecutive increases required at least 4 weeks apart, but time to progression will be determined at time of first PSA showing increase &gt; 50% above baseline *Note, upper confidence interval was not reached*</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate-Specific Antigen (PSA)/Serological Progression</measure>
    <time_frame>From study enrollment to progression per PSA criteria (for life)</time_frame>
    <description>Serological Progression (sPD) - increase in PSA to &gt;50% above lowest level recorded on study. Two consecutive increases required at least 4 weeks apart, but time to progression will be determined at time of first PSA showing increase &gt; 50% above baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Investigational Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Oral Folic Acid, once per day for 7 days preceding pemetrexed dose, continued daily, and for 21 days after the last dose of pemetrexed.
Vitamin B12, 1000ug intramuscular injection 7 days preceding pemetrexed dose, and every three cycles thereafter on the same day of pemetrexed administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12</intervention_name>
    <description>All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented adenocarcinoma of the prostate

          -  Clinically refractory or resistant to hormone therapy as assessed by progression
             following at least one hormonal therapy (orchiectomy or luteinizing hormone-releasing
             hormone (LHRH) agonist)

          -  One prior taxane based chemotherapy regimen for HRPC

          -  Documented progression of disease after one taxane based prior chemotherapy regimen
             for HRPC. Progression is defined as at least one of the following:

          -  An increase in PSA &gt; 50% over nadir value on prior Taxane-based therapy

          -  Progression of measurable disease as defined by RECIST

          -  Progression of bone disease as defined by the appearance of one or more new bone
             lesions or worsening symptoms

          -  Orchiectomy or testosterone levels &lt; 50 ng/dL maintained by LHRH agonist

          -  Prior chemotherapy, or other experimental anticancer agents must be completed &gt; 4
             weeks prior to being registered for protocol therapy

          -  Palliative radiotherapy must be completed at least 14 days prior to registration.

        Exclusion Criteria:

          -  Intravenous radio-isotopes therapy must be completed at least 6 weeks prior to
             registration

          -  No brain metastasis that are untreated and/or not controlled and/or still requiring
             corticosteroids

          -  No history of other malignancies within 5 years prior to being registered for protocol
             therapy, except for adequately treated basal or squamous cell skin cancer

          -  No history of uncontrolled psychiatric illness or serious systemic disease, including
             active infection, uncontrolled hypertension

          -  No surgery or significant traumatic injury within 21 days prior to being registered
             for protocol therapy

          -  Patients must be willing to interrupt aspirin or other non-steroidal anti-inflammatory
             agents for a 5-day period (8 day period for long acting agents such as piroxicam)

          -  Patients must be willing to take folic acid or vitamin B12 supplementation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Sweeney, M.B.B.S.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical &amp; Surgical Specialists, LLC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Cancer Center (MCGOP)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, P.C.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Hematology/Oncology of S. Michigan</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates S.J., P.A.</name>
      <address>
        <city>Mt. Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Medical Oncology &amp; Hematology</name>
      <address>
        <city>Drexel Hill</city>
        <state>Pennsylvania</state>
        <zip>19026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology-Hematology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hoosieroncologygroup.org/</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <results_reference>
    <citation>Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009 Dec;20(12):1971-6. doi: 10.1093/annonc/mdp244. Epub 2009 Jul 15.</citation>
    <PMID>19605506</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>December 17, 2015</results_first_submitted>
  <results_first_submitted_qc>June 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2016</results_first_posted>
  <last_update_submitted>June 18, 2016</last_update_submitted>
  <last_update_submitted_qc>June 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Christopher Sweeney, MBBS</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pemetrexed 500mg/m^2</title>
          <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Toxicity Analysis</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Response Analysis</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pemetrexed 500mg/m^2</title>
          <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="58" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Prostate-Specific Antigen (PSA)</title>
          <description>Prostate-Specific Antigen (PSA) is a protein produced by the prostate in men. Elevated PSA levels (&gt;4ng/mL) can be an indicator of infection or cancer of the prostate.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.2" lower_limit="0.8" upper_limit="1015.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Karnofsky Performance Status (KPS)</title>
          <description>Karnofsky Performance Status (KPS) is a general indicator of a subject's well being and ability to carry on daily activities. The KPS scale ranges from 0-100 in 10 unit increments where 100=Normal; no complaints; no evidence of disease and 0=Dead</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="70" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pain Score</title>
          <description>Patients self-scored their pain on a scale of 0-10 where 0=no pain and 10=extreme pain</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Opiate Use</title>
          <units>Intramuscular morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" lower_limit="0" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastatic Sites</title>
          <description>Number of patients who had metastatic disease present at the specified site at trial entry</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visceral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days Since Last Docetaxel</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>29-90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>91-180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Overall PSA Response</title>
        <description>Best overall Prostate-Specific Antigen (PSA) response
PSA response is defined by a greater than or equal to 50% decline in PSA confirmed by a second PSA value at least 4 weeks after the first PSA response timepoint PSA Stable Disease is defined as less than a 50% decline in PSA and less than a 50% increase in PSA from baseline PSA progression is defined as greater than or equal to a 50% increase in PSA compared to baseline</description>
        <time_frame>Start of treatment until disease progression/recurrence (for life)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall PSA Response</title>
          <description>Best overall Prostate-Specific Antigen (PSA) response
PSA response is defined by a greater than or equal to 50% decline in PSA confirmed by a second PSA value at least 4 weeks after the first PSA response timepoint PSA Stable Disease is defined as less than a 50% decline in PSA and less than a 50% increase in PSA from baseline PSA progression is defined as greater than or equal to a 50% increase in PSA compared to baseline</description>
          <units>percentage of participatns</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;50% decline in PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="1" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="9" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="52" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>From study enrollment until death (for life)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="13" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OBJECTIVE Overall Response Rate</title>
        <description>Response Evaluation Criteria in Solid Tumors (RECIST). Objective overall response rate is defined as Complete Response (CR) + Partial Response (PR)
Per RECIST:
CR= Disappearance of all target and non-target lesions and normalization of tumor marker level PR= Disappearance of all target lesions and persistence of non-target lesion(s) or maintenance of tumor marker level above normal limits OR at least a 30% decrease in the sum of the longest diameter, taking as reference the baseline sum longest diameter and disappearance of all non-target lesions or persistence of non-target lesion(s) or maintenance of tumor marker level above normal limits</description>
        <time_frame>Start of treatment until disease progression/recurrence (for life)</time_frame>
        <population>Patients who had measurable disease per RECIST 1.1 at baseline. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter &gt;20 mm using conventional techniques or &gt;10 mm with spiral CT scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>OBJECTIVE Overall Response Rate</title>
          <description>Response Evaluation Criteria in Solid Tumors (RECIST). Objective overall response rate is defined as Complete Response (CR) + Partial Response (PR)
Per RECIST:
CR= Disappearance of all target and non-target lesions and normalization of tumor marker level PR= Disappearance of all target lesions and persistence of non-target lesion(s) or maintenance of tumor marker level above normal limits OR at least a 30% decrease in the sum of the longest diameter, taking as reference the baseline sum longest diameter and disappearance of all non-target lesions or persistence of non-target lesion(s) or maintenance of tumor marker level above normal limits</description>
          <population>Patients who had measurable disease per RECIST 1.1 at baseline. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter &gt;20 mm using conventional techniques or &gt;10 mm with spiral CT scan.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with PR with meas. dis. per RECIST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="1" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with SD maintained at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="20" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Clinical Benefit</title>
        <description>A clinical benefit is defined as an improvement for at least 3 consecutive weeks in at least one of the following parameters without any sustained worsening in any other:
&gt; 50% reduction in analgesic consumption or &gt; 50% reduction in pain intensity or &gt; 20 point gain in performance status.</description>
        <time_frame>Any time among evaluable subjects (for life)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Clinical Benefit</title>
          <description>A clinical benefit is defined as an improvement for at least 3 consecutive weeks in at least one of the following parameters without any sustained worsening in any other:
&gt; 50% reduction in analgesic consumption or &gt; 50% reduction in pain intensity or &gt; 20 point gain in performance status.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="20" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability</title>
        <description>Safety and Tolerability was evaluated by reporting the percentage of patient who experienced grade 3 or 4 toxicities using Common Terminology Criteria for Adverse Events CTCAE v3.0 criteria. CTCAE grades the severity of an adverse event from 1-5 where 1=least severe and 5=death.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Safety and Tolerability was evaluated by reporting the percentage of patient who experienced grade 3 or 4 toxicities using Common Terminology Criteria for Adverse Events CTCAE v3.0 criteria. CTCAE grades the severity of an adverse event from 1-5 where 1=least severe and 5=death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="27" upper_limit="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="2.3" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RFC1 G80A Genotype</title>
        <description>Samples for RFC1 G80A pharmacogenetic analysis were collected at screening</description>
        <time_frame>Screening</time_frame>
        <population>Samples were available from 46 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>RFC1 G80A Genotype</title>
          <description>Samples for RFC1 G80A pharmacogenetic analysis were collected at screening</description>
          <population>Samples were available from 46 patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/G Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G/G Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Progression per Response Evaluation Criteria in Solid Tumors (RECIST) or Prostate-Specific Antigen (PSA) Progression RECIST PD=at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions PSA progression=increase in PSA to &gt;50% above lowest level recorded on study. Two consecutive increases required at least 4 weeks apart, but time to progression will be determined at time of first PSA showing increase &gt; 50% above baseline *Note, upper confidence interval was not reached*</description>
        <time_frame>Study enrollment until progression per RECIST or PSA (for life)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Progression per Response Evaluation Criteria in Solid Tumors (RECIST) or Prostate-Specific Antigen (PSA) Progression RECIST PD=at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions PSA progression=increase in PSA to &gt;50% above lowest level recorded on study. Two consecutive increases required at least 4 weeks apart, but time to progression will be determined at time of first PSA showing increase &gt; 50% above baseline *Note, upper confidence interval was not reached*</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1">The upper confidence interval was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Prostate-Specific Antigen (PSA)/Serological Progression</title>
        <description>Serological Progression (sPD) â increase in PSA to &gt;50% above lowest level recorded on study. Two consecutive increases required at least 4 weeks apart, but time to progression will be determined at time of first PSA showing increase &gt; 50% above baseline</description>
        <time_frame>From study enrollment to progression per PSA criteria (for life)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed 500mg/m^2</title>
            <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Prostate-Specific Antigen (PSA)/Serological Progression</title>
          <description>Serological Progression (sPD) â increase in PSA to &gt;50% above lowest level recorded on study. Two consecutive increases required at least 4 weeks apart, but time to progression will be determined at time of first PSA showing increase &gt; 50% above baseline</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of Treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pemetrexed 500mg/m^2</title>
          <description>Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Pemetrexed: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DIC (DISSEMINATED INTRAVASCULAR COAGULATION)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN / CARDIAC/HEART</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE (ASTHENIA, LETHARGY, MALAISE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / PELVIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATOBILIARY/PANCREAS - OTHER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA(ANC &lt;1.0 X 10E9/L, FEVER &gt;=38.5 DEGREES C)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH GRADE 3 OR 4 NEUTROPHILS (ANC &lt;1.0 X 10E9/L) / CATHETER-RELATED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / SKIN (CELLULITES)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN / BONE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNEA (SHORTNESS OF BREATH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VESSEL INJURY-ARTERY / EXTREMITY-LOWER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>VESSEL INJURY-VEIN / EXTREMITY-LOWER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>EDEMA: LIMB</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>EDEMA: TRUNK/GENITAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <counts group_id="E1" events="44" subjects_affected="21" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>LYMPHATICS - OTHER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES (ANC/AGC)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA - OTHER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>CARDIAC GENERAL - OTHER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR AND NODAL ARRHYTHMIA / ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLASHES/FLUSHES</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR/VISUAL - OTHER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / EYE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / EYE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>VISION-BLURRED VISION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>WATERY EYE (EPIPHORA, TEARING)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="17" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DISTENSION/BLOATING, ABDOMINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DRY MOUTH/SALIVARY GLAND (XEROSTOMIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL - OTHER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HEARTBURN/DYSPEPSIA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI / ANUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MUCOSITIS/STOMATITIS (CLINICAL EXAM) / ORAL CAVITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MUCOSITIS/STOMATITIS (FUNCTIONAL/SYMPTOMATIC) / ORAL CAVITY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="34" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / ABDOMEN NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / INTESTINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / ORAL CAVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / RECTUM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / STOMACH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PETECHIAE/PURPURA (HEMORRHAGE/BLEEDING INTO SKIN OR MUCOSA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION (DYSGEUSIA)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS - OTHER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>FATIGUE (ASTHENIA, LETHARGY, MALAISE)</sub_title>
                <counts group_id="E1" events="65" subjects_affected="41" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>FEVER (IN THE ABSENCE OF NEUTROPENIA, WHERE NEUTROPENIA IS DEFINED AS ANC &lt;1.0 X 10E9/L)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / BACK</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / EXTREMITY-LIMB- HAND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / HEAD/HEADACHE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / PERINEUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / SCALP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN - OTHER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN - OTHER FEET</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / BACK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / EXTREMITY-LIMB</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / PELVIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>RIGORS/CHILLS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS (INCLUDING SNEEZING, NASAL STUFFINESS, POSTNASAL DRIP)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY - OTHER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA (ANC &lt;1.0 X 10E9/L, FEVER &gt;=38.5 DEGREES C)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION - OTHER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / BLADDER (URINARY)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / LUNG (PNEUMONIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / SKIN (CELLULITIS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / ABDOMEN NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / BLADDER (URINARY)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / LYMPHATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / SKIN (CELLULITES)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / UPPER AIRWAY NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALBUMIN, SERUM-LOW (HYPOALBUMINEMIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>ALKALINE PHOSPHATASE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (SERUM GLUTAMIC PYRUVIC TRANSAMINASE)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>AST, SGOT(SERUM GLUTAMIC OXALOACETIC TRANSAMINASE)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>CREATININE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>GLUCOSE, SERUM-HIGH (HYPERGLYCEMIA)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HEMOGLOBINURIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>SODIUM, SERUM-LOW (HYPONATREMIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS (NON-SEPTIC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>EXTREMITY-LOWER (GAIT/WALKING)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>EXTREMITY-UPPER (FUNCTION)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINE-RANGE OF MOTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS, GENERALIZED OR SPECIFIC AREA (NOT DUE TO NEUROPATHY) / EXTREMITY-LOWER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS, GENERALIZED OR SPECIFIC AREA (NOT DUE TO NEUROPATHY) / WHOLE BODY/GENERALIZED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE - OTHER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / BONE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / EXTREMITY-LIMB</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / JOINT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / MUSCLE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / JOINT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COGNITIVE DISTURBANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>EXTRAPYRAMIDAL/INVOLUNTARY MOVEMENT/RESTLESSNESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>NEUROLOGY - OTHER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>NEUROPATHY: MOTOR</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>NEUROPATHY: SENSORY</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / NEURALGIA/PERIPHERAL NERVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MOOD ALTERATION / AGITATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION / ANXIETY</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION / DEPRESSION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION / ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>INCONTINENCE, URINARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / BLADDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY - OTHER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>URINARY FREQUENCY/URGENCY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION (INCLUDING NEUROGENIC BLADDER)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>URINE COLOR CHANGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GYNECOMASTIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION, GU / PROSTATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / BREAST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / PROSTATE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DYSPNEA (SHORTNESS OF BREATH)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, PULMONARY/UPPER RESPIRATORY / NOSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>NASAL CAVITY/PARANASAL SINUS REACTIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN / CHEST/THORAX NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY - OTHER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATOLOGY/SKIN - OTHER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>HAIR LOSS/ALOPECIA (SCALP OR BODY)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>NAIL CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PRURITUS/ITCHING</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>RASH: ACNE/ACNEIFORM</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>RASH: ERYTHEMA MULTIFORME (E.G., STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>RASH: HAND-FOOT SKIN REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>INR (INTERNATIONAL NORMALIZED RATIO OF PROTHROMBIN TIME)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>MUCOSITIS/STOMATITIS (CLINICAL EXAM) / ORAL CAVITY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PTT (PARTIAL THROMBOPLASTIN TIME)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PETECHIAE/PURPURA (HEMORRHAGE/BLEEDING INTO SKIN OR MUCOSA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Smith</name_or_title>
      <organization>Hoosier Cancer Research Network</organization>
      <phone>317-921-2050</phone>
      <email>jsmith@hoosiercancer.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

